Statement from ALS Canada regarding dexpramipexole research results

Today Biogen Idec reported results from a Phase 3 trial investigating dexpramipexole (dex) in people with amyotrophic lateral sclerosis (ALS). The company said that the trial failed to show slowing of functional decline or improved survival and failed to demonstrate efficacy. Based on these results, the company is discontinuing development of dexpramipexole in ALS. Earlier […]

9th edition of the Fondation André-Delambre Symposium

From left to right : Drs. Steve Perrin, Stanley Appel, Nobel Laureate Stanley Prusiner and Jean-Pierre Julien Quebec City – The 9th Annual Symposium on ALS Fondation André-Delambre was held on September 20 and 21 at Laval University in Quebec City. The organizers of the Symposium, Jean-Pierre Julien and Jasna Kriz, had invited 24 internationally renowned […]

Advertisement by ALS Canada